Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940518 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
A Phase 2 study of Clear Cell Renal Carcinoma and Ivonescimab, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06940518 is a Phase 2 study of Clear Cell Renal Carcinoma and Ivonescimab that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06940518, a Phase 2 study of Clear Cell Renal Carcinoma and Ivonescimab, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
Conditions Studied
Interventions
- DRUG Ivonescimab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2030-01-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06940518
The ClinicalTrials.gov registry entry for NCT06940518 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Clear Cell Renal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Ivonescimab is the first listed.
NCT06940518 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06940518 about?
NCT06940518 is a clinical study titled "Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma". To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
What is the current status of trial NCT06940518?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-02. Estimated completion is 2030-01-19.
What conditions does trial NCT06940518 study?
This clinical trial studies the following conditions: Clear Cell Renal Carcinoma, Ivonescimab.
What interventions are being tested in trial NCT06940518?
The interventions under investigation include: Ivonescimab (DRUG).
Who is sponsoring clinical trial NCT06940518?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940518 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.